Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas Sells 3,000 Shares

by · The Markets Daily

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, valued at approximately $155,000. The trade was a 32.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daphne Karydas also recently made the following trade(s):

  • On Tuesday, March 31st, Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock traded up $1.14 during mid-day trading on Wednesday, reaching $25.13. The stock had a trading volume of 1,646,383 shares, compared to its average volume of 2,014,045. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -12.26 and a beta of 0.57. The company has a 50-day moving average price of $27.64 and a two-hundred day moving average price of $30.13. Mineralys Therapeutics, Inc. has a one year low of $12.59 and a one year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its holdings in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after acquiring an additional 676 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares in the last quarter. Navalign LLC purchased a new stake in Mineralys Therapeutics in the 4th quarter worth approximately $33,000. Velan Capital Investment Management LP grew its holdings in Mineralys Therapeutics by 0.6% during the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after buying an additional 1,000 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Mineralys Therapeutics by 262.3% during the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MLYS has been the subject of several research reports. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, Bank of America increased their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

View Our Latest Research Report on Mineralys Therapeutics

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Further Reading